~~<i id='A94E80B791'><strike id='A94E80B791'><tt id='A94E80B791'><pre id='A94E80B791'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：knowledge 2025-09-27 13:10:09 - browse：34

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Takeda, Janssen join wearable maker to measure scratching

hotspot

knowledge

leisure time

focus

AlexHogan/STATPIKEVILLE,Ky.—STAT’smultiyearlegalbattletounsealsecretPurduePharmafilesinaKentuckycour

WSS

BIO selects John Crowley as new CEO

Novo acquires Inversago for up to $1 billion

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

U.K. Biobank has 500,000 peoples' genome sequences available

The history of OxyContin, told through Purdue Pharma documents

Pediatric cancer treatments threatened by a new FDA policy

knowledge

comprehensive

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Flagship Pioneering launches a new biotech in two countries

Duchenne breakthrough therapy leaves behind pioneering families

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

After affirmative action ruling, medical educators look to 'holistic review'

Diagnostic tests are hitting their mathematical limits

At least 13 dead in Texas as scorching temps continue

Some of the ways extreme heat will change life as we know it

Sports medicine is finally prioritizing gender equality

As biotech industry slumps, bioscience job market is upside down

knowledge

Large hospital system sues Multiplan for low

BIO selects John Crowley as new CEO

Covid's long

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

White House drug shortages task force keeps mum with Congress

Diagnostic tests are hitting their mathematical limits

leisure time

focus

focus

focus